Amyris partners with IDRI to create adjuvants for COVID-19 vaccine

Amyris (AMRS +4.7%) and Infectious Disease Research Institute (IDRI) has signed a binding term for a planned COVID-19 RNA (ribonucleic acid) vaccine technology program.

The program combines IDRI’s RNA vaccine platform with Amyris’ fermentation platform technology, with the goal to create semi-synthetic squalene-based vaccine adjuvants at scale.

Amyris expects first commercial supply of vaccine adjuvant by the end of this year and, assuming successful trials, could have a successful vaccine platform next year.

Additional details of the proposed program will be disclosed

https://seekingalpha.com/news/3595297-amyris-partners-idri-to-create-adjuvants-for-covidminus-19-vaccine